Home > News & Events > Chiesi Group signs an Option Agreement with...

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data

Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)

Date: 30/05/2019

Chiesi, an international research-focused healthcare Group (Chiesi Group) and Inhibrx, Inc. (“Inhibrx”), a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced today they entered into an agreement granting Chiesi Group an option to exclusively license development and commercial INBRX-101 outside of the United States and Canada where  Inhibrx will retain those rights.


INBRX-101 is an Fc-fusion protein based therapeutic candidate expected to enter clinical development in the middle of this year. INBRX-101 is a modified recombinant version of human alpha-1 antitrypsin, or AAT, for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. AATD is a rare genetically defined respiratory disease characterized by progressive destruction of lung tissue.



About Chiesi Group

Based in Parma, Italy, Chiesi Farmaceutici is an international research-oriented group with over 80 years' experience in the pharmaceutical sector and is present in 28 countries. The group researches, develops and commercializes innovative medicines in the respiratory disease, special care and rare disease therapeutic areas. The Group's Research & Development center is based in Parma (Italy) and integrated with 6 other important research and development groups in France, the USA, the UK and Sweden, to promote its pre-clinical, clinical and registration programs. The Group employs around 5,700 people. www.chiesi.com.


About Inhibrx, Inc.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X. For more information, please visit www.inhibrx.com.


Click here for the Inhibrx Press release